Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 106

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 106
---
 to approximately $712 thousand for the year ended December 31, 2024, compared
to approximately $1,125 thousand for the year ended December 31, 2023. The decrease resulted mainly from a decrease in professional fees
due to the recognition of prepaid issuance costs associated with the former initial public offering process, recognized as expense following
the entry into the business combination agreement, or BCA, with OceanTech Corp. during the second quarter of 2023 and additional expenses
associated with the BCA.

Finance income (expense)

Finance expenses decreased
by approximately $6,070 thousand, or 275.8%, to approximately $3,869 thousand finance income for the year ended December 31, 2024, compared
to approximately $2,201 thousand finance expense for the year ended December 31, 2023. The decrease resulted mainly from change in fair
value of convertible notes and a change in fair value of warrant liability.

Net income (loss)

Net loss decreased by
approximately $8,933 thousand to approximately $4,801 thousand net income for the year ended December 31, 2024, compared to $4,132 thousand
net loss for the year ended December 31, 2023. The decrease was mainly the result of an increase in our finance income and from the Horizon
2020 Grant.

Critical Accounting Policies and Estimates

We describe our significant
accounting policies and estimates in Note 2 to our annual financial statements contained elsewhere in this prospectus. We believe
that these accounting policies and estimates are critical in order to fully understand and evaluate our financial condition and results
of operations.

We prepare our financial
statements in accordance with U.S. GAAP.

In preparing these financial
statements, management has made judgments, estimates and assumptions that affect the application of our accounting policies and the reported
amounts recognized in the financial statements. On a periodic basis, we evaluate our estimates, including those related to share-based
compensation and derivatives. We base our estimates on historical experience, authoritative pronouncements and various other assumptions
that we believe to be reasonable under the circumstances. Actual results may differ from these estimates.

We evaluated the convertible
notes in accordance with ASC 470 "Debt", or ASC 470. The proceeds from the issuance of notes or loan with conversion features
that are determined to not be beneficial are allocated entirely to liabilities in accordance with ASC 470. As part of the convertible
loan fair value measurement, we use significant estimates which include